Radiopharm Theranostics Limited — Form 6-K
Reporting date: October 5, 2026. The company, an Australian foreign private issuer, furnished this Form 6-K to report an announcement published to the Australian Securities Exchange.
Business context and announcement
The filing identifies the announcement as “RAD Completes Meeting with US FDA for Development of RAD101.” The announcement itself is not included in the provided filing text, so the meeting’s outcomes and any development plans cannot be summarized.
Financial results and changes
This filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no comparison with a prior period.
Outlook, risks, and contingencies
The filing text does not provide a clear value or details for guidance, management commentary, risks, contingencies, or unusual items. It states that the report and exhibit are incorporated by reference into the company’s Form F-3 registration statement, subject to subsequent filings.
Key facts to verify
- Review Exhibit 99.1 or the ASX announcement for the FDA meeting’s conclusions, feedback, and any agreed next steps for RAD101.
- Check subsequent company disclosures for development timelines, regulatory requirements, funding needs, or material risks arising from the meeting.